What happened
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) said its subsidiary LightSolver signed a paid deal with Israel's Ministry of Defense to develop and deliver an LPU. The deal is with the ministry's Directorate of Defense Research Development.
It follows earlier proof-of-concept work with the directorate and moves the relationship to a multi-year framework. LightSolver has secured an initial order for the first 12 months. LPU stands for Laser Processing Unit, the photonic computing product LightSolver develops.
Senior ministry representatives formally signed the agreement. It covers intellectual property and technology usage rights.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Initial order period | 12 months | SEC 6-K, Exhibit 99.1 press release | |
| LightSolver defense market estimate (annual, global, up to) | $5 billion | SEC 6-K, Exhibit 99.1 press release | |
| Estimated defense market growth (CAGR, approximate) | 15% | SEC 6-K, Exhibit 99.1 press release |
Read more: CollPlant Biotechnologies (CLGN) company research
Why it matters
A government defense customer is now paying for LightSolver's technology after the earlier proof-of-concept work. That is the point for CollPlant holders. Chief Executive Dr. Ruti Ben Shlomi said the deal, together with an existing multi-year engineering program with Boeing, shows progress in turning technical validation into paid customer programs.
The release puts LightSolver's defense market at up to $5 billion a year worldwide, growing at about 15% a year, and cites Hyperion Research 2025. That is the company's estimate. It is a ceiling, not a measure of this contract.
OptimistFi has argued that CollPlant is a platform bet that needs partner funding before cash burn and dilution erode its option value. A paying defense customer fits the partner-funded part of that view. But the work is photonic computing, not collagen, so the effect is mixed.
The release itself warns that the directorate may not fund future phases and that the program could be delayed, reduced or terminated.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
The initial order covers only the first stretch of the engagement. The directorate's decision on funding later phases is the next test. CollPlant's next quarterly or annual report is where an update would appear.
A funded follow-on would strengthen OptimistFi's view that partners can carry development costs. A delay, cut or termination, all listed as risks in the release, would weaken it.
More from OptimistFi
- CLGN stock: research and coverage of CollPlant Biotechnologies
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Perps news: leveraged stocks, gold, FX and crypto on-chain
- Prop firms that fund crypto and stock perps traders: rules, prices and payouts
- Top perps movers today: stocks, commodities, FX and indices
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
Sources
- CollPlant press release, Exhibit 99.1 to Form 6-K — Press release dated Oct. 29, 2026 announcing LightSolver's paid collaboration with the Israel Ministry of Defense.
- CollPlant Form 6-K for October 2026 — Cover report furnishing the press release, signed by Deputy CEO and CFO Eran Rotem on Oct. 29, 2026.
Explore OptimistFi research on CollPlant Biotechnologies Ltd.: https://optimistfi.com/stocks/CLGN
Browse CollPlant Biotechnologies Ltd. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the CollPlant Biotechnologies Ltd. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
